BEIJING (Reuters) – Shanghai Fosun Pharmaceutical has signed a strategic cooperation agreement with Sinopharm Group to supply a coronavirus vaccine candidate developed by German firm BioNTech, it said on Monday.
BioNTech announced last month a potential deal with Fosun Pharma to supply 10 million doses of their candidate to Hong Kong and Macau.
The two Chinese firms will work together to set up a cold chain system to store and distribute the vaccine, Fosun Pharma said in a press release.
Separately, a unit of China National Pharmaceutical Group, Sinopharm Group’s parent company, is testing two vaccine candidates in final-stage human trials to combat the virus that has killed over 880,000 people worldwide.
(Reporting by Roxanne Liu and Twinnie Siu; Editing by Jan Harvey)
